semaglutide cost south africa Worth The Weight: Medicine's Gold Rush Newer Weight-Loss Drugs Not Cost-effective

Haque LY, Leggio L

found that bleeding complications were increased in DM after adjustment for other comorbidities and medications

Nat Rev Endocrinol 14(7):390403

Sustainable, clean weight management

The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty-five (35) at the time of initiation of GLP-1 therapy, or The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty (30) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: Heart failure with preserved ejection fraction, uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications , or chronic kidney disease stage 3a or above, or The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to twenty-seven (27) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: Pre-diabetes (as defined by American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease